ValiRx PLC - Result of AGM, Warrants & Directorate Change
ValiRx PLC
("ValiRx" or the "Company")
Result of AGM & Issue of Warrants
Director and PDMR Shareholding
Directorate Change
Details of the votes received will be available on the Company's website shortly.
Issue of Warrants
Pursuant to the Fundraising and in connection with the issuance of the Fee Shares the Company has issued 577,500,000 Fundraising Warrants. The Fundraising Warrants will be exercisable at a price of
In addition, the Company has issued 53,750,000 Broker Warrants. The Broker Warrants will be exercisable at the Issue Price. The Broker Warrants are exercisable at any time until the third anniversary of date of grant.
Terms used but not defined in this announcement have the same meaning as set out in the Company's announcement released at
Directorate Change
The Company announces that
The Board would like to thank Cathy for her valuable contribution to the Company during her tenure and wishes her every success in the future.
"I am committed to supporting the broader translation of academic science to patients and as such I think my time is best spent focusing on my leadership of the Milner Therapeutics Institute, University of Cambridge.
I am confident in the current management and scientific teams and that focusing the portfolio on later stage pre-clinical projects is important for the Company to deliver for shareholders.
I wish ValiRx and the team the best for the future."
"On behalf of the Board of VAL plc I would like to say a big thank you to Cathy for her scientific leadership in both her roles as CSO and more recently on the Board. Cathy leaves VAL in a much stronger position scientifically. We wish her well as she concentrates on her executive role at the Milner Therapeutics Institute."
The Directors of the Company take responsibility for this announcement.
*** ENDS ***
Engage with the ValiRx management team directly by asking questions, watching video summaries and seeing what other shareholders have to say. Navigate to our Interactive Investor hub here: https://valirx.com/s/cc8ef3
For more information, please contact:
|
Investor questions on this announcement We encourage all investors to share questions on this announcement via our investor hub |
|
|
ValiRx plc Dr |
Tel: +44 115 784 0026 |
|
Cairn Financial Advisers LLP (Nominated Adviser) |
Tel: +44 (0) 20 7213 0880 |
|
Shard Capital Partners LLP (Sole Broker) |
Tel: +44 (0) 20 7186 9000 |
|
V Formation (Public Relations) |
+44 (0) 115 646 5491 |
Subscribe to our news alert service: https://valirx.com/s/f298d1
Notes for Editors
About ValiRx
ValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.
ValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.
Using its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.
ValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.
Lead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.
ValiRx listed on the AIM Market of the London Stock Exchange in
For further information, visit: www.valirx.com
|
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 |
||||||||
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
|||||||
|
a. |
Name |
|
||||||
|
2 |
Reason for notification |
|
||||||
|
a. |
Position/Status |
Director
|
||||||
|
b. |
Initial notification/ Amendment |
Initial notification |
||||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||||
|
a. |
Name |
ValiRx PLC |
||||||
|
b. |
LEI |
213800VQKB9SJCQDET40 |
||||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||||
|
a. |
Description of the financial instrument, type of instrument |
Warrants over new Ordinary Shares exercisable at a price of
ISIN: GB00BLH13C52 |
||||||
|
b. |
Nature of the transaction |
Warrants as part of the Fundraising |
||||||
|
c. |
Price(s) and volume(s) |
|
|
|
|
|
||
|
|
Price(s) |
Volume(s) |
|
|||||
|
|
25,000,000 |
|
||||||
|
|
||||||||
|
d. |
Aggregated information - Aggregated Volume - Price |
N/A
|
||||||
|
e. |
Date of the transaction |
|
||||||
|
f. |
Place of the transaction |
Outside a trading venue
|
||||||
|
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 |
||||||||
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
|||||||
|
a. |
Name |
|
||||||
|
2 |
Reason for notification |
|
||||||
|
a. |
Position/Status |
Director
|
||||||
|
b. |
Initial notification/ Amendment |
Initial notification |
||||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||||
|
a. |
Name |
ValiRx PLC |
||||||
|
b. |
LEI |
213800VQKB9SJCQDET40 |
||||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||||
|
a. |
Description of the financial instrument, type of instrument |
Warrants over new Ordinary Shares exercisable at a price of
ISIN: GB00BLH13C52 |
||||||
|
b. |
Nature of the transaction |
Warrants as part of the Fundraising |
||||||
|
c. |
Price(s) and volume(s) |
|
|
|
|
|
||
|
|
Price(s) |
Volume(s) |
|
|||||
|
|
2,500,000 |
|
||||||
|
|
||||||||
|
d. |
Aggregated information - Aggregated Volume - Price |
N/A
|
||||||
|
e. |
Date of the transaction |
|
||||||
|
f. |
Place of the transaction |
Outside a trading venue
|
||||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE